Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody

Table 2

Proteins identified to decrease after tocilizumab treatment.

Protein name	Accession no.	Times of detection	Relative abundance (average)				Decrease ratio		Paired t-test P
			ctr	Before	4W	8W	Before/4W	Before/8W	Before versus 4W	Before versus 8W
C-reactive protein, pentraxin-related	55770842	5	1	13.507	4.107	2.124	17.928	15.085	0.252	0.037
Orosomucoid 1 precursor	167857790	6	1	6.130	1.725	0.775	13.070	7.750	0.124	0.041
Haptoglobin isoform 1 preproprotein	4826762	7	1	2.876	1.028	0.507	7.261	5.266	0.067	0.015
Serine proteinase inhibitor, clade A, member 1	50363221	7	1	3.278	1.403	1.025	3.974	3.318	0.051	0.008
Pregnancy-zone protein	162809334	7	1	1.592	0.755	0.633	2.126	2.966	0.010	0.009
Complement component 9 precursor	4502511	7	1	1.979	1.194	1.307	1.713	1.631	0.012	0.015
Leucine-rich alpha-2-glycoprotein 1	16418467	7	1	2.636	1.681	1.735	1.803	1.597	0.012	0.013

Accession number: accession number (gi) in the human RefSeq protein database of the National Center for Biotechnology Information, USA.
Times of detection: the number of samples in which the protein was detected.
Relative abundance: the ratio of the iTRAQ reporter ion to the 114 reporter ion (control).
Decrease ratio: the ratio of protein abundance between the first and seconed samples (Before/4W) and between the first and third samples (Before/8W).
Bold: increased by more than 1.5-fold.
Paired 𝑡-test 𝑃: the 𝑃 value of a paired 𝑡-test between the first and second samples (4W) or between the first and third samples (8W).
Bold: 𝑃<0.05.